Tumor Biology

, Volume 37, Issue 7, pp 9189–9196 | Cite as

Caveolin-1 affects tumor drug resistance in esophageal squamous cell carcinoma by regulating expressions of P-gp and MRP1

  • Song Zhang
  • Wenbo Cao
  • Mingjin Yue
  • Naigang Zheng
  • Tao Hu
  • Shengli Yang
  • Ziming Dong
  • Shixin Lu
  • Saijun Mo
Original Article


Esophageal squamous cell carcinoma (ESCC) is the most common cancer in China, and multidrug resistance (MDR) remains one of the biggest problems in ESCC chemotherapy. In this study, we aimed to investigate the mechanism of Caveolin-1, an integral membrane protein, on regulating ESCC MDR. First, immunohistochemistry was used to check the protein expression of Caveolin-1, MDR-related protein of P-glycoprotein (P-gp), and multidrug resistance protein 1 (MRP1) in 84 pathologically characterized ESCC tissues, matched adjacent tumor, and adjacent normal-looking tissues. The results showed that Caveolin-1 expression level was elevated in ESCC tissues than that of matched adjacent tumor and adjacent normal-looking tissues (P < 0.05), and the expression of Caveolin-1 has close correlation with P-gp and MRP1 during tumor genesis of ESCC (P = 0.034, P = 0.009, respectively). Then, Caveolin-1 overexpression and knockdown were used to investigate its effect on expressions of P-gp and MRP1 in ESCC cell line Ec9706. The messenger RNA (mRNA) and protein expression levels of P-gp and MRP1 were checked by real-time quantitative reverse transcription-PCR (qRT-PCR) and Western blot (WB). The results showed that Caveolin-1 overexpression significantly promotes the mRNA and protein expression of MRP1 (P < 0.05), while almost has no effect on the mRNA and protein expression of P-gp (P > 0.05); Cavoelin-1 knockdown inhibits the mRNA and protein expressions of both P-gp and MRP1 (P < 0.05). The similar result was found in another ESCC cell line Eca109. So, it is concluded that Caveolin-1 affects ESCC MDR by regulating the expressions of P-gp and MRP1; therefore, it can be taken as a significant marker and target in tumor therapy.


Caveolin-1 Multidrug resistance P-gp MRP1 Esophageal squamous cell carcinoma 



We thank Jinfeng Miao, Lei Cao, Qian Wu, Xiangyong Tian, Tao Wang, and Yalan Jiang for their suggestions and technical assistance. This work was supported by the National Natural Science Foundation of China (No. 81101686) and Foundation of He’nan Educational Committee (Nos. 12A310008 and 15A310029).

Compliance with ethical standards

Conflicts of interest


Supplementary material

13277_2015_4778_MOESM1_ESM.doc (687 kb)
ESM 1 (DOC 687 kb)
13277_2015_4778_MOESM2_ESM.doc (602 kb)
ESM 2 (DOC 602 kb)


  1. 1.
    Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411–24.CrossRefPubMedGoogle Scholar
  2. 2.
    Kerbel RS. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev. 2001;20:1–2.CrossRefPubMedGoogle Scholar
  3. 3.
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.CrossRefPubMedGoogle Scholar
  4. 4.
    Eckford PDW, Sharom FJ. ABC efflux pump-based resistance to chemotherapy drugs. Chem Rev. 2009;109:2989–3011.CrossRefPubMedGoogle Scholar
  5. 5.
    Naito S, Yokomizo A, Koga H. Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int J Urol. 1999;6:427–39.CrossRefPubMedGoogle Scholar
  6. 6.
    Mo SJ, Yang SL, Cui Z. New glimpses of caveolin-1 functions in embryonic development and human diseases. Front Biol. 2011;6:367–76.CrossRefGoogle Scholar
  7. 7.
    Couet J, Li S, Okamoto T, Scherer PS, Lisanti MP. Molecular and cellular biology of caveolae: paradoxes and plasticities. Trends Cardiovasc Med. 1997;7:103–10.CrossRefPubMedGoogle Scholar
  8. 8.
    Senetta R, Stella G, Pozzi E, Sturli N, Massi D, Casson P. Caveolin-1 as a promoter of tumour spreading: when, how, where and why. J Cell Mol Med. 2013;17:325–36.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Nunez-Wehinger S, Ortiz RJ, Diaz N, Diaz J, Lobos-Gonzalez L, Quest AF. Caveolin-1 in cell migration and metastasis. Curr Mol Med. 2014;14:255–74.CrossRefPubMedGoogle Scholar
  10. 10.
    Quest AF, Lobos-González L, Nuñez S, Sanhueza C, Fernández JG, Aguirre A, et al. The caveolin-1 connection to cell death and survival. Curr Mol Med. 2013;13:266–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Lavie J, Fiucci G, Liscovitch M. Up-regulation of caveolae and caveolar constituents in multidrug-resistant cancer cells. J Biol Chem. 1998;273:32380–3.CrossRefPubMedGoogle Scholar
  12. 12.
    Linge A, Meleady P, Henry M, Clynes M, Kasper M, Barth K. Bleomycin treatment of A549 human lung cancer cells results in association of MGr1-Ag and caveolin-1 in lipid rafts. Int J Biochem Cell Biol. 2011;43:98–105.CrossRefPubMedGoogle Scholar
  13. 13.
    Wang NN, Zhao LJ, Wu LN, He MF, Qu JW, Zhao YB, et al. Mechanistic analysis of taxol-induced multidrug resistance in an ovarian cancer cell line. Asian Pac J Cancer Prev. 2013;14:4983–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Zhu H, Cai C, Chen J. Suppression of P-glycoprotein gene expression in Hs578T/Dox by the overexpression of caveolin-1. FEBS Lett. 2004;576:369–74.CrossRefPubMedGoogle Scholar
  15. 15.
    Shajahan AN, Wang A, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. 2007;282:5934–43.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu Z, Ren S, Chen X. Construction of caveolin-1 RNA interfering eukaryotic expressing vector and its influence biological behavior of human gastric cancer cells. Cancer Res Clin (Chinese). 2010;22:98–104.Google Scholar
  17. 17.
    Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Wen J, Zheng B, Hu Y, Zhang X, Yang H, Li Y, et al. Comparative proteomic analysis of the esophageal squamous carcinoma cell line EC109 and its multi-drug resistant subline EC109/CDDP. Int J Oncol. 2010;36:265–74.PubMedGoogle Scholar
  19. 19.
    To KK, Yu L, Liu S, Fu J, Cho CH. Constitutive AhR activation leads to concomitant ABCG2-mediated multidrug resistance in cisplatin-resistant esophageal carcinoma cells. Mol Carcinog. 2012;51:449–64.CrossRefPubMedGoogle Scholar
  20. 20.
    Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Dig Dis Sci. 2010;55:2545–51.CrossRefPubMedGoogle Scholar
  21. 21.
    Gan SY, Zhong XY, Xie SM, Li SM, Peng H, Luo F. Expression and significance of tumor drug resistance related proteins and beta-catenin in esophageal squamous cell carcinoma. Chin J Cancer. 2010;29:300–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Ando T, Ishiguro H, Kimura M, Mitsui A, Mori Y, Sugito N, et al. The overexpression of caveolin-1 and caveolin-2 correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. Oncol Rep. 2007;18:601–9.PubMedGoogle Scholar
  23. 23.
    Beghin D, Forestier F, Noël-Hudson MS, Gavard L, Guibourdenche J, Farinotti R, et al. Modulation of endocrine and transport functions in human trophoblasts by saquinavir and nelfinavir. Eur J Obstet Gynecol Reprod Biol. 2010;152:55–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Meena AS, Sharma A, Kumari R, Mohammad N, Singh SV, Bhat MK. Inherent and acquired resistance to paclitaxel in hepatocellular carcinoma: molecular events involved. PLoS One. 2013;8, e61524.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Davidson B, Goldberg I, Givant-Horwitz V, Nesland JM, Berner A, Bryne M, et al. Caveolin-1 expression in ovarian carcinoma is MDR1 independent. Am J Clin Pathol. 2002;117:225–34.CrossRefPubMedGoogle Scholar
  26. 26.
    Lavie Y, Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconj J. 2000;17:253–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Barakat S, Demeule M, Pilorget A, Régina A, Gingras D, Baggetto LG, et al. Modulation of p-glycoprotein function by caveolin-1 phosphorylation. J Neurochem. 2007;101:1–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhang Y, Qu X, Teng Y, Li Z, Xu L, Liu J, et al. Cbl-b inhibits P-gp transporter function by preventing its translocation into caveolae in multiple drug-resistant gastric and breast cancers. Oncotarget. 2015;6:6737–48.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Zhang Y, Qu X, Li C, Fan Y, Che X, Wang X, et al. miR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 2015;36:2277–85.CrossRefPubMedGoogle Scholar
  30. 30.
    Gomà A, Mir R, Martínez-Soler F, Tortosa A, Vidal A, Condom E, et al. Multidrug resistance protein 1 localization in lipid raft domains and prostasomes in prostate cancer cell lines. Oncol Targets Ther. 2014;7:2215–25.Google Scholar
  31. 31.
    Nakamura M, Nakatani K, Uzawa K, Ono K, Uesugi H, Ogawara K, et al. Establishment and characterization of a cisplatin-resistant oral squamous cell carcinoma cell line, H-1R. Oncol Rep. 2005;14:1281–6.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Song Zhang
    • 1
  • Wenbo Cao
    • 2
  • Mingjin Yue
    • 3
  • Naigang Zheng
    • 2
  • Tao Hu
    • 2
  • Shengli Yang
    • 2
    • 4
  • Ziming Dong
    • 2
    • 4
  • Shixin Lu
    • 1
  • Saijun Mo
    • 2
    • 4
  1. 1.The First Affiliated Hospital of Zhengzhou UniversityZhengzhouChina
  2. 2.Department of Basic Science of Oncology, School of Basic Medical SciencesZhengzhou UniversityZhengzhouChina
  3. 3.Henan Tianxing Education and Media Company, LimitedZhengzhouChina
  4. 4.Collaborative Innovation Center of Henan Province for Cancer ChemopreventionZhengzhouChina

Personalised recommendations